Oramed Pharmaceuticals Hits New 52-Week High of $3.76, Up 75% Yearly

Oramed Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 3.76 on February 25, 2026. This achievement underscores the company's notable performance in the pharmaceuticals and biotechnology sector, where it operates as a microcap entity with a market capitalization of USD 128 million. Over the past year, Oramed Pharmaceuticals has demonstrated impressive growth, with a remarkable 75.12% increase in stock value, significantly outpacing the S&P 500's performance of 12.95%. The company has reported a substantial net profit growth of 264.2%, reflecting its positive financial trajectory. Additionally, the return on equity stands at 10.05%, indicating effective management of shareholder equity. Despite facing challenges, Oramed's recent quarterly results have shown a pre-tax profit of USD 39.49 million and a net profit of USD 32.15 million, marking a turnaround after previous negative quarters. The stock's price-to-book ratio of 0.63 suggests a valuation that may attract attention. With high institutional holdings at 20.05%, Oramed Pharmaceuticals continues to position itself as a noteworthy player in its industry.